Oncolytics Biotech shares surge 19.62% after-hours after announcing FDA engagement for pancreatic cancer trial plans.

Oncolytics Biotech (ONCY) surged 19.62% in after-hours trading, driven by Lake Street Capital initiating coverage with a "Buy" recommendation on August 14, 2025, and the company regaining Nasdaq compliance on July 22, 2025. The stock also gained momentum following presentations of Pelareorep’s clinical data at key opinion leader events in July, highlighting its potential in pancreatic and gastrointestinal cancers. These developments addressed prior regulatory concerns and reinforced investor confidence in the company’s pipeline advancements, aligning with the significant after-hours price rally.